Abstract Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are critical events associated with an accelerated loss of lung function, increased morbidity, and excess mortality. AECOPD are heterogeneous in nature and this may directly impact clinical decision making, specifically in patients with frequent exacerbations. A 'frequent exacerbator' is a sub-phenotype of chronic obstructive pulmonary disease (COPD) and is defined as an individual who experiences two or more moderate-to-severe exacerbations per year. This distinct subgroup has higher mortality and accounts for more than half of COPD-related hospitalizations annually. Thus, it is imperative to identify individuals at risk for frequent exacerbations and choose optimal strategies to minimize risk for these events. New paradigms for using combination inhalers and the introduction of novel oral compounds provide expanded treatment options to reduce the risk and frequency of exacerbations. The goals of managing frequent exacerbators or patients at risk for AECOPD are: (1) maximizing bronchodilation; (2) reducing inflammation; and (3) targeting specific molecular pathways implicated in COPD and AECOPD pathogenesis. Novel inhaler therapies including combination long-acting muscarinic agents plus long-acting beta agonists show promising results compared with monotherapy or a long-acting beta agonist inhaled corticosteroid combination in reducing exacerbation risk among individuals at risk for exacerbations and among frequent exacerbators. Likewise, oral medications including macrolides and phosphodiesterase-4 inhibitors reduce the risk for AECOPD in select groups of individuals at high risk for exacerbation. Future direction in COPD management is based on the identification of various subtypes or 'endotypes' and targeting therapies based on their pathophysiology. This review describes the impact of AECOPD and the challenges posed by frequent exacerbators, and explores the rationale for different pharmacologic approaches to preventing AECOPD in these individuals.
Introduction
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death in the USA, reaching this rank in 2008, nearly a decade earlier than projected by the Global Burden of Disease Study [1, 2] . Acute exacerbations of COPD (AECOPD) significantly alter the natural course of the disease by accelerating the decline in lung function and impacting quality of life, mortality, and healthcare utilization [3] [4] [5] [6] [7] . Admissions for COPD exacerbations have an estimated in-patient mortality of 10%, and 4-year mortality following an exacerbation can be as high as 45% [8] . These events also remain a major driver of COPDrelated healthcare cost, with estimated annual healthcare costs nine-to tenfold greater for individuals who experience AECOPD as compared with non-exacerbators, and these costs increase with the frequency and severity of exacerbations [2, 9] .
Owing to its effects on patients' health status and its economic burden, preventing and mitigating the impact of AECOPD is the cornerstone of COPD management along with smoking cessation and symptom palliation. Here, we review recent evidence behind pharmacologic approaches to prevent exacerbations in conjunction with the evolving understanding of exacerbation phenotypes. We performed a series of literature searches on PubMed for topics on frequent exacerbations and therapies including key searches using the terms 'frequent exacerbation', 'exacerbation', 'COPD exacerbation', 'exacerbation risk', 'endotype', 'long-acting beta-agonist', 'long-acting muscarinic antagonist', 'combination inhaler', 'inhaled corticosteroid', 'macrolide', and 'roflumilast. ' 
Defining Chronic Obstructive Pulmonary Disorder Exacerbations and Frequent Exacerbators
An acute exacerbation of COPD is defined as a sustained worsening beyond the normal day-to-day variation of the individual's condition from a stable state that is acute in onset and warrants additional treatment [9, 10] . These events are typically characterized by the presence of one or more of the three cardinal symptoms, an increase or newonset dyspnea, sputum production, and sputum purulence plus the presence of supporting symptoms including wheezing, cough, fever, upper respiratory symptoms, tachypnea, or tachycardia [11] . Infections are implicated in the majority of AECOPD, but other etiologies including exposure to noxious substances from the environment or allergens, occult cardiac ischemia, and pulmonary thromboembolism account for up to 30% of events. These complex interactions result in acute airway and lung parenchymal inflammation, which lead to dynamic hyperinflation and symptom development [12, 13] . These interactions between the host and environment plus perturbations of many molecular biologic pathways help explain the heterogeneity of exacerbations. In turn, this heterogeneity accounts for some of the challenges clinicians face with treating these critical events.
The spectrum of COPD exacerbation ranges widely in its severity and frequency. Hurst et al. defined the 'frequent exacerbator' as an individual who experiences two or more moderate to severe exacerbations per year. The prevalence of frequent exacerbators was reported as 22% in GOLD 2, 33% in GOLD 3, and 47% in GOLD 4 COPD in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study [14] and was reported as 41.4% for GOLD 1-2 and 58.6% for GOLD 3 and 4 COPD in a post-hoc analysis of POET-COPD [15] . In ECLIPSE, the authors identified lower forced expiratory volume in 1 s (FEV 1 ), poor quality of life, increased serum white blood cell count, gastroesophageal reflux, and having a prior exacerbation as risk factors for the frequent exacerbator phenotype and demonstrated that frequent AECOPD occur in moderate as well as severe COPD [14] . However, determinants for changing from an 'infrequent exacerbator' to a frequent exacerbator are not well understood. Thus, all individuals with any risk factor for becoming a frequent exacerbator should be considered at high risk for becoming frequent exacerbators. Three hostspecific features that convey risk for frequent exacerbations include persistent inflammation, reduced lung function and hyperinflation, and comorbid conditions.
Inflammation, Endotypes, Microbiota, and Exacerbations
Owing to the complex host-environmental interactions related to AECOPD, many pathways and molecular targets have been implicated in frequent exacerbations. For example, non-specific inflammatory markers such as interleukin (IL)-6 and IL-8 are elevated in the airways of frequent exacerbators measured during periods of clinical stability during exacerbations [16] . Likewise, elevated serum levels of C-reactive protein measured in the recovery period are associated with a shorter time until the next exacerbation, implicating persistent inflammation in frequent exacerbations [17] . Given the heterogeneity of COPD, new insights into its pathogenesis suggest that COPD comprises multiple distinct disorders, or endotypes. An endotype is described as ''a subtype of a condition, which is defined by a distinct functional or pathophysiological mechanism'' [18] . The two well-defined cell-based endotypes in COPD patients are the neutrophilic endotype and the eosinophilic or T helper-2 endotype [19, 20] . The neutrophilic endotype is implicated in COPD and AECOPD pathogenesis owing to its role in regulating host defense, inflammation, and protease release. Individuals with the neutrophilic endotype have elevated levels of persistent inflammation when in a non-exacerbating steady state and are associated with bacterial infection during AECOPD [21] . In fact, the majority of COPD exacerbations are neutrophil mediated and individuals who have neutrophil-predominant AECOPD have poorer outcomes compared with patients with eosinophilic exacerbations [22] . Thus, therapies targeting pathways implicated in neutrophil signaling are in nascent stages of development and have been tested in preclinical studies. These agents are discussed below in detail.
Although airway eosinophilia is not a distinct feature of COPD, between 20 and 40% of individuals with COPD have increased sputum and blood eosinophil counts [23] . Airway biopsies taken at the time of exacerbation in this endotype have a 30-fold increase in the total number of eosinophils, suggesting a pathologic role in AECOPD [24] . This distinct COPD subgroup responds well to corticosteroid treatment [25, 26] . Therapies for this endotype are discussed below.
COPD exacerbations differ in pathophysiology based on the etiology of the event and response to the inciting element, through activation of inflammatory pathways, response to infectious triggers, or contributions of comorbid conditions including cardiovascular disease. Observational studies have proposed that the frequent exacerbator phenotype has increased viral susceptibility and experiences a greater proportion of viral exacerbations than infrequent exacerbators [27, 28] . This distinction might be important in developing treatment strategies as viruses appear to stimulate more eosinophilic activity as compared with bacteria [21] .
Perturbations to the microbiome contribute to AECOPD risk by changes to the local microbiota, as well as through increased susceptibility to the acquisition of new strains of viral and bacterial infections. The lower airways are colonized by bacteria in 25-50% of individuals with COPD [11, 29] . Chronic colonization of the lower airways is an independent stimulus for airway inflammation and AECOPD [30, 31] . Furthermore, changes to the airways microbiome occur at the onset of AECOPD [32] . [3] . Other physiologic impairments of lung function, including resting and dynamic hyperinflation, also alter the risk for AECOPD. Frequent exacerbators have a higher degree of dynamic hyperinflation even in a stable state. This not only contributes to symptoms of dyspnea, but also lowers the capacity to compensate for acute events [33, 34] . Bronchodilators help reduce dynamic hyperinflation by relieving small airway obstruction and hence 'resetting' the exacerbation threshold.
Impact of Comorbid Conditions on Exacerbation Risk
Frequent exacerbators, now recognized to be a distinct phenotype in COPD, also have increased mortality. Because accelerated atherosclerosis and increased arterial stiffness have been demonstrated in COPD patients, efforts are now directed at understanding the relationship between cardiovascular comorbidities and disease progression in this subgroup of COPD patients [35, 36] . Patel et al. compared arterial stiffness as a marker of cardiac risk in frequent COPD exacerbators to identify patients with frequent exacerbations. This study noted that frequent COPD exacerbators had greater arterial stiffness than infrequent exacerbators and arterial stiffness increased acutely during COPD exacerbations, particularly with airway infection, and remained elevated for up to 8 weeks following resolution of the acute event [37] . These findings raise the concern that repeated exacerbations could result in cumulative cardiac injury, which can potentially explain increased mortality in these patients. Therefore, there is an increased interest in exploring effects of cardioprotective drugs on lung function and exacerbation rates in COPD patients. Angiotensin receptor blockers and HMG-CoA reductase inhibitors (statins) were the first drug classes to be studied experimentally. Angiotensin receptor blockers failed to show an improvement in lung function and statins failed to reduce exacerbation rates in these trials [38, 39] . As compared with the results from the studies of angiotensin receptor blockers and statins in mitigating AECOPD risk, findings from observational studies of betablocker use in COPD are encouraging, with one study showing a reduction in AECOPD risk [Incidence risk ratio (IRR) 0.73; confidence interval (CI) 0.60-0.90] in individuals receiving beta-blockers compared with participants who did not use beta blockers. This improvement in AECOPD risk was independent of the severity of lung function impairment and underlying cardiovascular disease [40] . In addition to cardioprotective effects, murine models have shown that long-term beta-blocker administration decreases bronchoconstriction by upregulating airway beta receptors and decreasing mucus production [41, 42] . Based on these findings, a clinical trial investigating the impact of metoprolol on AECOPD risk is ongoing [43] .
Clinical Challenge in the Management of a Frequent Exacerbator
Despite important advances in therapeutic management of COPD, it remains a progressive disease. Although there have been several drugs recently approved for the treatment of COPD, the majority are inhaled therapies from the three main classes of medications used in treating COPD, namely long-acting beta agonists (LABA), long-acting muscarinic antagonists (LAMA), and inhaled corticosteroids (ICS). Of these classes and their combinations, few have shown benefits in reducing exacerbation frequency in clinical trials. Thus, approaches to ameliorating the risk for AECOPD falls into the following general categories: (1) maximizing bronchodilation through the use of long-acting bronchodilators, (2) reducing inflammation through the use of ICS, chronic macrolide therapy, phosphodiesterase-4 inhibitors, and other compounds; and (3) applying precision medicine approaches through discovery and implementation of new treatments targeted at specific molecular pathways implicated in COPD and AECOPD pathogenesis to guide therapy. These approaches are covered below. While tobacco cessation, pulmonary rehabilitation, and supplemental oxygen use are vital in the management of COPD, these topics will not be covered in depth in this review.
Inhaled Long-Acting Bronchodilators
Long-acting bronchodilators remain the cornerstone of COPD management. LAMA, LABA, and LAMA/LABA combinations are the bronchodilators used in managing COPD. Bronchodilators play a pivotal role in preventing COPD exacerbations by improving baseline expiratory flow limitation and air trapping, hence increasing the difference between baseline air trapping and critical air trapping at which exacerbation occurs [34, 44] .
Long-Acting Muscarinic Antagonist Monotherapy
Tiotropium is the most extensively studied LAMA and remains the most prescribed bronchodilator for COPD management. The results of trials evaluating LAMA monotherapy on AECOPD risk reduction are shown in , an aqueous form of tiotropium, has similar efficacy to the dry powder formula in preventing exacerbations (HR 0.95; CI 0.93-1.03) [48, 49] .
Since 2012, several new LAMA agents have been approved for maintenance therapy in COPD. Aclidinium bromide, umeclidinium bromide, and glycopyrronium bromide are comparable to tiotropium in regard to FEV 1 improvement over placebo [50] [51] [52] [53] [54] [55] . Glycopyrronium reduced the risk of moderate and severe exacerbation by 31% as compared with placebo in the GLOW-1 study over 26 weeks (HR 0.69, 0.50-0.95, p \ 0.023) and reduced AECOPD risk by up to 34% (p \ 0.0001) as compared with placebo over 52 weeks in the GLOW-2 study [56, 57] . Neither aclidinium nor umeclidinium has been associated with AECOPD risk reduction.
Long-Acting Beta-Agonist Monotherapy
The role for LABAs in COPD management is well established, as LABAs improve lung function and quality of life, and reduce AECOPD in patients with moderate-to-severe COPD. A meta-analysis has shown that LABA monotherapy reduces AECOPD events by 21% (CI 10-31) [58] . However, there are limited data comparing the efficacy of LABA with LAMA monotherapy in reducing AECOPD. POET-COPD is the largest RCT designed to directly [59] . The INVIGORATE trial compared the efficacy of indacaterol with tiotropium in individuals at high risk for exacerbation [60] . Both treatments offered comparable improvements in lung function, but tiotropium outperformed indacaterol in reducing exacerbation risk. Among individuals receiving tiotropium, the annualized rate of exacerbations was lower (0.73 vs. 0.90 exacerbations per year; p \ 0.0001) and the time to first moderate exacerbation was longer by 20% (HR 1.20, p = 0.0012) compared with the indacaterol group. These results confirm findings from the POET-COPD study despite the low rate of AECOPD in INVIGORATE [60] . Extrapolating from these findings, LABA monotherapy should not be used in frequent exacerbators and instead LAMA or combination inhaler therapies should be considered.
Inhaled Corticosteroids
Inhaled corticosteroids have been used for decades in managing COPD owing to their anti-inflammatory effects and their clinically obvious benefit in patients with asthma. Although combination therapy with LABA/ICS has been shown to reduce exacerbation rates, the place of ICS monotherapy in COPD management is still debatable. Most of the data comes from observational studies, meta-analyses, and systematic reviews of small RCTs. Results from these trials should be interpreted with caution because of variations in exacerbation definitions and inclusion criteria between different trials. Agarwal et al. conducted a systematic review and meta-regression of 11 RCTs comparing ICS monotherapy with placebo in COPD patients. ICS use was associated with only a modest benefit in preventing COPD exacerbations compared with placebo (18% relative risk reduction; risk ratio 0.82; CI 0.73-0.92) and no linear relationship was found between drug efficacy and the level of lung function as measured by FEV 1 [61] . This is in contrast to earlier meta-analyses that included smaller trials and showed a significant benefit of ICS monotherapy in preventing COPD exacerbation in patients with severe lung disease (FEV 1 \50%) [62] [63] [64] [65] . ISOLDE, a RCT, compared fluticasone with placebo and showed no differences in the annual rate of FEV 1 decline but fluticasone use was associated with a 25% reduction in annual exacerbation rate as compared with placebo (p = 0.026). However, it is unclear if patients in both groups were receiving optimum COPD treatment (combination therapy with LAMA, LABA and short-acting beta-agonists) at baseline [66] .
Inhaled corticosteroid use is associated with an increased risk of pneumonia, which can further affect morbidity and mortality in frequent exacerbators. A population-based cohort study following over 160,000 COPD patients for 18 years found that ICS use was associated with a 69% increase in the risk of serious pneumonia as compared with patients who were not using ICS [67] . These findings confirm observations from the TORCH trial where fluticasone-containing regimens had a higher incidence of pneumonia as compared with placebo [68] .
Thus, the WISDOM trial evaluated the stepwise withdrawal of ICS in patients with severe but stable COPD who were receiving concomitant LABA and LAMA [69] . Participants in WISDOM were low risk for AECOPD. This trial showed that stepwise removal of ICS did not affect the rates of moderate and severe exacerbation as compared with the group who continued ICS therapy, which aligns with the systematic review conducted by Agarwal et al. [69] . However, more studies are needed to evaluate the role of ICS in patients with frequent exacerbations. Thus, it might be safe to withdraw ICS in COPD patients who are at low risk of exacerbations. These changes are reflected in the 2017 GOLD update [70] .
Combination Inhaler Therapies
There has been accelerated research in the past few years to develop LAMA/LABA as well as new LABA/ICS formulations based on the rationale of maximizing bronchodilation, reducing AECOPD risk, and improving medication compliance among individuals with COPD. The summary of the results for trials investigating combination inhalers on mitigating AECOPD risk is shown in Table 2 .
Long-Acting Beta-Agonists/Inhaled Corticosteroids
The majority of studies evaluating the efficacy of LABA therapy in mitigating AECOPD risk have evaluated LABA in combination with ICS. Combination of salmeterol/fluticasone has shown to significantly reduce bronchial inflammation, as evidenced by a reduction in CD45 leukocytes and CD8 and CD4 cells along with a decrease in cells expressing genes for the proinflammatory mediators in bronchial biopsy specimens of patients treated with a LABA/ICS combination vs. placebo [71] . Strong clinical data favoring the use of LABA/ICS to reduce AECOPD comes from the TRISTAN study in 2003, a RCT comparing a salmeterol/fluticasone combination inhaler to each of salmeterol monotherapy, fluticasone monotherapy, and placebo in 1465 patients with moderateto-severe COPD, chronic bronchitis, and at least one adverse event from COPD per year for the 3 years prior to enrollment. All treatment groups had significantly reduced numbers of exacerbations as compared with the placebo group at 1 year. The rate of AECOPD fell by 25% in the combination group, by 20% in the salmeterol group, and 19% in the fluticasone group as compared with placebo, and the effect was most pronounced in patients with FEV 1 \50%. Overall, the mean rate of exacerbation per patient per year were 0.97 in the combination group as compared with 1.30 in the placebo group [72] .
The TORCH study, another RCT comparing salmeterol monotherapy, fluticasone monotherapy, combination salmeterol/fluticasone, and placebo in moderate-to-severe COPD, validated these findings. Combination therapy with salmeterol/fluticasone reduced the annual rate of exacerbations as compared with placebo (0.85 vs. 1.13), corresponding to a RR of 0.75 (95% CI 0.69-0.81; p \ 0.001) and a number needed to treat of four to prevent one exacerbation per year [73] . Similar findings were present for salmeterol monotherapy compared with placebo. There was a slight benefit for AECOPD risk reduction in salmeterol/fluticasone compared with salmeterol or fluticasone monotherapy. Szafranski et al. conducted a similar trial comparing a twice-daily budesonide (320 lg) and formoterol (9 lg) combination in a single inhaler, budesonide (200 lg) alone, formoterol (4.5 lg) alone, or placebo over a 1-year period in individuals with a FEV 1 \50% and who reported at least one severe AECOPD in the year prior to enrollment. Budesonide/formoterol reduced the number of severe exacerbations by 24% compared with placebo, by 23% compared with formoterol, and by 11% compared with budesonide, suggesting a role for budesonide/formoterol combination in high-risk patients [74] .
A follow-up study using a similar design compared the efficacy of the same dose of budesonide and formoterol combination with high-dose ICS (budesonide 400 lg), formoterol (9 lg), and placebo. LABA/ICS use prolonged the time to first exacerbation and reduced the exacerbation rate compared with placebo (23.6%) and formoterol (25.5%) but not with budesonide alone (13.6%). Monotherapy with either inhaler did not affect the rate of exacerbation as compared with placebo [75] . Recently, the combination of vilanterol and fluticasone was associated with a 8.4% (CI 1.1-15.2, p = 0.02) lesser rate of exacerbations compared with usual care in moderate-to-severe COPD [76] . Taken together, these data suggest that ICS/ LABA combination therapy is warranted for a risk reduction in COPD exacerbations and possibly frequent exacerbators. There are no head-to-head trials comparing different LABA/ICS combination inhalers on exacerbation rates. However, no differences in efficacy in FEV 1 response and safety were noted between salmeterol/fluticasone and formoterol/budesonide combinations in a small study [77] . Despite this clear role of LABA/ICS in COPD, there has been a focused interest in identifying unique phenotypes where LABA/ICS may be more efficacious. Recent studies have identified a subset of COPD patients with significant eosinophilic airway inflammation, i.e., the eosinophilic endotype. Interestingly, these patients exhibit great response to inhaled LAMA/ICS or ICS inhalation therapy. Pavord et al. conducted a pooled analysis of three trials with a LABA/ICS combination to study if a higher blood eosinophil count was associated with a greater reduction in exacerbation frequency with LABA/ICS combinations. The trial populations were divided into two groups: \2% blood eosinophilia and C2% eosinophilia. Among patients with C2% eosinophils, LABA/ICS was associated with significant reduction in the rate of AECOPD vs. tiotropium in both INSPIRE and TRISTAN studies with an exacerbation RR of 0.75 (CI 0.60-0.92, p = 0.006) and 0.63 (CI 0.50-0.79, p \ 0.001) when compared with placebo, respectively. However, there was no difference in exacerbation rate in the SCO30002 trial [26] . Pascoe et al. made similar observations in a post hoc analysis from two RCTs using the same stratification. LABA/ICS combination therapy (vilanterol/fluticasone) reduced exacerbations by 29% compared with vilanterol alone (mean 0.91 vs. 1.28 exacerbations per patient per year; p \ 0.0001) in patients with eosinophil counts of C2% or higher, and by 10% (0.79 vs. 0.89; p = 0.2827) in patients with eosinophil counts \2%, suggesting selective benefit of ICS in patients who have eosinophilic driven inflammation during AECOPD [78] .
Long-Acting Muscarinic Antagonists/LongActing Beta-Agonists
As opposed to the LABA/ICS combination that has bronchodilatory and anti-inflammatory properties, LAMA/ LABA only have bronchodilator activity [79] . However, the LAMA/LABA combination may synergistically increase the therapeutic benefit by simultaneously affecting beta adrenergic and muscarinic receptors, even at submaximal doses. The first LAMA/LABA approved in USA was umeclidinium-vilanterol after studies demonstrated improvements in lung function, exercise tolerance, and symptoms in patients with COPD [80, 81] . Improvements in lung function were greater among individuals treated with combination umeclidinium/vilanterol compared with fluticasone/salmeterol among patients with moderate-tosevere COPD who were at low risk for AECOPD [82] . Similar improvements in lung function were reported with the addition of umeclidinium to fluticasone/vilanterol therapy [83] . However, no trials have specifically looked at the effect of umeclidinium/vilanterol on exacerbation risk. Other LAMA/LABAs including indacaterol-glycopyrronium, tiotropium-olodaterol, and glycopyrronium-formoterol have shown sustained improvements in FEV 1 and dyspnea when compared with placebo and usual care. However, evidence regarding their efficacy to reduce the frequency of COPD exacerbation is sparse [84] [85] [86] . The strongest evidence for LAMA/LABA use to prevent exacerbations comes from the FLAME trial, which compared indacaterol/glycopyrronium with salmeterol/fluticasone in COPD patients at high risk for AECOPD as defined by having at least one exacerbation in the past year [84] . The combination of indacaterol/glycopyrronium was superior to salmeterol/fluticasone in reducing the annual rate of exacerbation by 11% (RR 0.89; 0.83-0.96; p = 0.003). The indacaterol-glycopyrronium group also had a longer time to the first exacerbation than the salmeterol-fluticasone group (71 vs. 51 days, p \ 0.001), representing a 16% lower risk. A subgroup analysis of high-risk patients (classified as GOLD B and GOLD D) demonstrated that LAMA/LABA was most efficacious in preventing moderate-to-severe exacerbations with little impact on reducing mild events. Based on the results of FLAME, the GOLD 2017 COPD management guidelines now suggest that LABA/LAMA combination be used as first-line therapy for high-risk, i.e., GOLD B and D, patients [70] .
6 Oral Agents
Macrolide Antibiotics
Macrolides have long been a mainstay in treatment of AECOPD and provide symptomatic relief, improve the exacerbation-free interval, and aid peak flow recovery [11, 87, 88] . In addition to the anti-bacterial activity, macrolides also have immunomodulatory and anti-inflammatory properties [89, 90] . Because of these effects, macrolides have been extensively studied as agents to prevent exacerbations. Erythromycin was the first macrolide to reduce exacerbation frequency in COPD patients. Seemungal et al. randomized 115 patients with moderate-to-severe COPD to either 250 mg erythromycin twice daily or placebo for 12 months. Exacerbation frequency was significantly reduced in the macrolide arm as compared with the placebo arm, with a RR of 0.648 (CI 0.489-0.859; p = 0.003). The erythromycin group also had a longer median time to first exacerbation compared with placebo (271 vs. 89 days, p = 0.02) [91] .
Likewise, the MACRO study, a multicenter RCT, demonstrated that azithromycin (250 mg/day) reduced exacerbation frequency compared with placebo when taken for a 1-year period. Individuals at high risk for AECOPD, defined as those who received systemic corticosteroids or had an emergency room visit in the previous year because of AECOPD or who were receiving longterm oxygen therapy, were included in the study [92] . Azithromycin decreased the frequency of exacerbations as compared to placebo (1.48 exacerbations per patient year vs. 1.83, p \ 0.001) and improved the quality of life. A subgroup analysis further suggested that azithromycin treatment reduces sputum proline-glycine-proline, a proinflammatory chemokine implicated in COPD pathogenesis and progression, providing additional information on the anti-inflammatory mechanism of azithromycin [93] . A subsequent study evaluating the effect of daily azithromycin use in neutrophilic COPD showed that a reduction in exacerbation frequency was also accompanied with a reduction in sputum neutrophilia as well as IL-8 and bacterial load [94] . A sub-group analysis of the MACRO trial suggested that chronic azithromycin therapy may be more efficacious in older individuals and mild-to-moderate COPD but less efficacious among current smokers [95] . The COLUMBUS trial evaluated the efficacy of azithromycin 500 mg three times weekly vs. placebo in reducing exacerbation frequency among frequent or 'super' exacerbators, defined as individuals who had three or more AECOPD within the prior year [96] . The authors found a significant risk reduction among those randomized to azithromycin compared with placebo (RR 0.58, CI 0.42-0.79; p = 0.001). These results are summarized in Table 3 .
Studies have also compared 'pulsed' antibiotics with continuous antibiotics and a recent meta-analysis of seven RCTs showed that use of a continuous prophylactic macrolide showed significant reduction in exacerbation frequency, whereas the use of a pulsed prophylactic macrolide was associated with a non-significant reduction in exacerbation frequency [97] . Macrolides are, however, pro-arrhythmogenic and a large retrospective study showed that patients who took azithromycin for 5 days had an increased risk of cardiovascular death as compared with patients who took no antibiotics (HR 2.88; CI 1.79-4.63; p \ 0.001) [98] . Moreover, hearing loss was more common in the azithromycin group in the MACRO study. Hence, caution must be exercised in selecting COPD patients for prophylactic macrolide treatment, keeping in mind its otologic and cardiovascular side-effect profile.
Phosphodiesterase-4 Inhibitor (Roflumilast)
Roflumilast is a second-generation phosphodiesterase-4 inhibitor that promotes the effective inhibition of chemotaxis, cytokine production in vitro, and reduces the number of leukocytes in sputum samples of COPD patients [99, 100] . Roflumilast is the only oral anti-inflammatory medication indicated by the US Food and Drug Administration to reduce exacerbation risk in patients with severe COPD-associated chronic bronchitis and a history of exacerbations as shown in Table 4 .
In a phase III, randomized controlled dose-ranging trial, roflumilast had a dose-dependent reduction in exacerbation risk compared with placebo (1.03 events per year in 250 lg/day vs. 0.75 events per year in 500 lg/day vs. 1.13 events per year in placebo). Roflumilast also led to a modest dose-dependent improvement in post-bronchodilator FEV 1 [101] . Following the encouraging results of this trial, two RCTs showed that roflumilast improved lung function in patients with moderate-to-severe COPD but had no impact on exacerbation risk in these groups as a whole [102, 103] . As the result of these findings, a post-hoc analysis of COPD sub-phenotypes showed a reduction in exacerbation frequency in patients with chronic bronchitis by 26.2% compared with placebo (p = 0.001). However, patients receiving concomitant ICS experienced an 18.8% reduction in exacerbation risk compared with placebo, whereas patients not using ICS exhibited no clinical benefit compared with placebo [104] . Based on these results, the REACT trial was designed to address the efficacy of the coated-tablet formulation of roflumilast in preventing exacerbations in high-risk patients, including frequent exacerbators and in individuals receiving LABA/ICS maintenance therapy. This multi-national randomized placebo-controlled study showed that the rate of moderate-tosevere exacerbation was 13.2% lower in the roflumilast group than in the placebo group (RR 0.868; CI 0.753-1.002, p = 0.0529) in frequent COPD exacerbators already receiving LABA/ICS inhaled therapy [105] .
The RE2SPOND trial was designed to evaluate the efficacy of the non-coated roflumilast tablet formulation in individuals at high risk for AECOPD despite combination therapy with LABA/ICS with or without LAMA. While roflumilast failed to reduce moderate and severe exacerbations in the overall population (RR 0.92; CI 0.81-1.04; p = 0.163), roflumilast reduced the exacerbation rates in individuals with a history of more than three exacerbations and/or one or more hospitalizations in the prior year by 39% as compared with placebo (RR 0.61; 95% CI 0.39-0.95; p = 0.030) [106] .
Roflumilast is generally well tolerated and the adverse effects are class specific for phosphodiesterase-4 inhibitors. The most common adverse effects include intractable diarrhea, nausea, weight loss, depression, and insomnia. In the landmark trial by Calverely et al., rates of adverse effects and drug discontinuation were noted to be 67 and 14%, respectively [102] . Other small retrospective studies have shown that the discontinuation rate of roflumilast can be as high as 49-84% related to these side effects [107, 108] . However, most side effects occur within 4-12 weeks of initiation of roflumilast and are self-limited [109] . The side-effect profile of roflumilast should always be weighed against the benefit in individual patients. In patients who are likely to benefit the most from roflumilast, correct education on the gastrointestinal and neuropsychiatric adverse effects is paramount.
Anti-Oxidant and Mucolytic Agents
N-acetyl cysteine (NAC) is a therapeutic agent with mucolytic as well as potent antioxidant and anti-inflammatory properties. NAC has been postulated to ameliorate the acute inflammatory state during exacerbations because of its role as a free radical scavenger. The BRONCHUS trial evaluated the efficacy of NAC 600 mg daily vs. placebo on lung function and AECOPD risk among 523 individuals with moderate-to-severe COPD over a 3-year period [110] . Although BRONCHUS trial failed to demonstrate efficacy for either lung function improvement or mitigation of exacerbation risk, groups of investigators felt this was owing in part to the relatively low dose of NAC used as well as the inclusion of low-risk individuals in the trial. More recent studies have evaluated the use of higher dose NAC in subjects at higher risk for AECOPD, including frequent exacerbators. Zheng at al. randomized 990 patients with moderate-to-severe COPD to NAC 600 mg twice daily vs. placebo for 1 year and found that NAC reduced AECOPD events compared with placebo (1.49 vs. 1.6 events/year respectively, exacerbation risk ratio 0.78, CI 0.67-0.90; p = 0.0011) [111] . These findings were confirmed in a similar study (1.59 events/year in NAC 600 mg twice per In both these studies, NAC was not beneficial in low-risk or mild COPD patients, again emphasizing the need to tailor COPD management based on heterogeneous subgroups [112] . A meta-analysis suggests that higher doses ([1200 mg/day) may be required to prevent AECOPD among individuals with chronic bronchitis and COPD [113] .
Carbocysteine is a compound with mucolytic and antioxidant properties similar to those of NAC. The efficacy of carbocysteine was evaluated in a cohort of COPD patients with frequent exacerbations living in China. Compared with placebo, carbocysteine 1500 mg/day reduced the number of exacerbations per year (1.01 vs. 1.35 events/ year, p = 0.004) [114] . However, few study participants were receiving ICS-containing therapies, limiting the generalizability of these findings to a broader population. Despite these limitations, both NAC and carbocysteine are relatively innocuous compounds and are well tolerated, even in frequent exacerbators.
Other Measures

Vaccinations
Respiratory infections are important triggers for AECOPD [27] . Notably, 16-60% of viral induced AECOPD are associated with influenza infection [115, 116] . Influenza vaccinations reduce the risk of hospitalization from COPD exacerbation and improve mortality. Poole et al. estimated that inactivated influenza vaccination reduced rates of AECOPD after 3 weeks following vaccination. There was no increase in early exacerbation as a result of the vaccine itself [117] . Despite clear indications for pneumococcal vaccination in reducing the risk for community-acquired pneumonia in COPD, the efficacy of pneumococcal vaccine preparations in preventing COPD exacerbation is less clear. Furumoto et al. demonstrated fewer infectious exacerbations in COPD subjects in the first year following vaccinations among individuals with COPD who received both pneumococcal and influenza vaccines compared with influenza vaccine alone (10.3 vs. 26.3%, p = 0.037) [116] . The GOLD guidelines recommend both influenza and pneumococcal vaccination for all COPD patients [118] .
Non-Pharmacologic Measures
Smoking cessation is one critical intervention that improves mortality in COPD patients and is the only intervention that affects the decline in lung function [119, 120] . Smoking cessation is associated with a reduced risk for AECOPD, and the risk reduction is directly proportional to the time since abstinence [119, 121] . Pulmonary rehabilitation is a non-pharmacologic intervention that improves exercise capacity, dyspnea, and quality of life in patients with stable COPD [122] . Pulmonary rehabilitation is also efficacious in reducing hospital readmission and improving quality of life and mortality if started within 30 days of hospitalization for AECOPD [123] . Thus, both of these interventions should be high priority in all COPD patients.
Novel Therapies and Future Directions
Given the complexity and heterogeneity of underlying pathophysiologic mechanisms in COPD and AECOPD, there is an increased inclination towards exploring therapeutic strategies targeted at specific molecular pathways or distinct endotypes. As mentioned above, eosinophilia has become a major target for precision medicine in COPD since the identification of the eosinophilic endotype [124] [125] [126] . In addition to using LABA/ICS in this subgroup, various T helper-2 cytokines involved in eosinophilic pathways are now being evaluated as potential therapeutic targets in these patients. Interleukin-5 is a candidate cytokine as it regulates the differentiation, proliferation, survival, and activation of eosinophils [127] . Benralizumab is an anti-IL-5 monoclonal antibody that significantly improved FEV 1 from baseline as compared with placebo (0.13 vs. -0.06 L, respectively; p = 0.014). There was a non-statistically significant reduction in AECOPD rates by 31% in a subgroup of patients with baseline blood eosinophil levels of 200 cells/lL or more who received benralizumab as compared with placebo. Results of this pre-specified subgroup analysis are encouraging and warrant additional trials in patients with predominantly eosinophilic inflammation (p = 0.26) [128] . Additional studies exploring the effect of other anti-IL-5 and anti-IL-13 therapies are underway [129, 130] .
Neutrophils are key mediators of inflammation in COPD and become the predominant cell type as disease progresses. Thus, therapies targeting the inhibition of neutrophil actions as well as downstream mediators in the signaling pathway are being developed. Chemokine receptors on neutrophils, including CXCR2, play a central role in the chemotaxis and adhesion of neutrophils in lungs [131] . Development and testing of CXCR2 antagonists are in nascent stages, which by inhibiting migration and activation of neutrophils in lungs offers a potential target to prevent lung damage during AECOPD. Two selective CXCR2 receptors, MK-7123 and AZD5069, have been evaluated for their efficacy and safety profile in COPD patients. MK-7123 was studied at three drug concentrations (10, 30 , and 50 mg) as compared with placebo and the 50-mg treatment dose significantly improved FEV 1 as compared with placebo. However, exacerbation rates were not significantly different in both the groups (29.9 vs. 31.2%, HR 0.96; CI 0.64-1.44), though studies were not powered for this endpoint. Neutropenia, defined as an absolute neutrophil count \1000/mm 3 , developed in 11% of patients in the study drug group as compared with 1% in the placebo group after 6 months of treatment. AZD5069, an alternate CXCR2 antagonist, was well tolerated in a phase IIb dose-ranging study. Although there was a trend towards improvement in FEV 1 in the treatment groups as compared with placebo, the study was not powered to detect differences in lung function as an efficacy parameter. Neutropenia occurred in 7% of patients in the intervention group. Despite a reduction in neutrophil counts, higher rates of infections were not seen in the study groups in both the trials as compared with placebo [132, 133] .
P38-mitogen activated protein kinase (MAPK) inhibition is another potential target for COPD patients. P38-MAPK mediates the expression of inflammatory markers, such as tumor necrosis factor a, IL-1, IL-6, and IL-8, which lead to characteristic chronic lung inflammation in COPD and are overexpressed in active smokers. PH-797804 is a novel p38-MAPK inhibitor, which has been shown to improve FEV 1 and dyspnea after 6 weeks of use as compared with placebo in patients with moderate-to-severe COPD [134] . However, another selective p38-MAPK inhibitor, losmapimod, failed to show any improvement in lung function as compared with placebo [135] . A post-hoc analysis of this trial showed that losmapimod reduced the exacerbation rate in a subgroup of patients with\2% blood eosinophil count at baseline [136] . Because of the lack of favorable results, further efforts for PH-797804 and losmapimod drug development are on hold. Therapeutically targeting specific endotypes is a novel approach and holds potential for bringing a paradigm shift in COPD management in the future.
As discussed above, chronic bacterial colonization contributes to the risk for AECOPD through altering host defense and modulating immune responses. Bacterial lysates, reconstituted mixtures of bacterial antigens present in the lower airways of individuals with COPD, act as immunostimulants through the induction of cellular maturation, stimulating lymphocyte chemotaxis, and increasing opsonization when administered to individuals with COPD [137] [138] [139] . Small studies have shown mixed results in evaluating the efficacy of bacterial lysates in patients with COPD. A systematic review of 13 studies showed that the main treatment effect in preventing exacerbations was only found in smaller studies and the combined analysis showed no difference between the intervention and placebo groups in reducing exacerbation frequency in COPD patients [140] . Most of these trials were conducted prior to the routine use of long-acting bronchodilators and ICS in COPD. However, the recent study by Braido et al. evaluated the efficacy of Ismigen Ò , a bacterial lysate, in reducing exacerbations in individuals with moderate-to-severe COPD who were at high risk for exacerbations [137] . They found no difference in the exacerbation rate between Ismigen Ò and placebo or the time to first exacerbation. However, in secondary analyses, they observed a longer time to subsequent exacerbation and fewer days hospitalized for severe AECOPD. In an open-label prepost study, Koatz et al. evaluated the utility of OM-85 bacterial lysate at reducing respiratory infections in a mixed population of participants with asthma, allergic rhinitis, and COPD who had three or more respiratory events in the preceding year [141] . The authors observed a 34% reduction in exacerbation frequency in the COPD subgroup (25 events vs. 38 events in the previous year). These findings suggest a potential role for bacterial lysates in managing the frequent exacerbator, though larger and more robust clinical trials are needed to verify these findings.
Conclusions
The frequent exacerbator is a distinct COPD phenotype characterized by two or more exacerbations per year and poses a major healthcare burden owing to increased costs, morbidity, and mortality. In clinical practice, identification of this subgroup is important for selecting appropriate management strategies aimed at reducing AECOPD risk and progression of lung function impairment. Approaches to mitigating AECOPD risk should include multi-modal interventions including smoking cessation, pulmonary rehabilitation, combination inhaler therapy, and the use of daily azithromycin or roflumilast. Although treatments for the frequent exacerbator will often include the use of many of these interventions, we recommend initiating therapy with a LAMA over a LABA for individuals who have previously had one exacerbation in the previous year. We recommend the use of LAMA/LABA over LABA/ICS as the next step in therapy for individuals who have an additional exacerbation despite LAMA monotherapy. For the frequent exacerbator, we recommend 'triple therapy' with LAMA/LABA/ICS. As the phenotype of patients treated with 'triple therapy' shifts from frequent to infrequent exacerbators, we recommend stopping ICS given the risk for pneumonia. Long-term macrolide or roflumilast therapy should be considered in individuals who remain high risk despite 'triple therapy'. Often, the choice for oral therapy is dependent on the individual's clinical phenotype and the side-effect profile of the medication. Novel agents targeting specific pathways implicated in AECOPD are currently under development and show promise in early-stage trials.
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